Sarkopenie und Kachexie: Muskelabbau und Mangelernährung

Schlüsselwörter

Insulin-like growth factor 1 - Stresshormone - proinflammatorische Zytokine - Myostatin

Keywords

Insulin-like growth factor 1 - stress hormones - proinflammatory cytokines - myostatin

Literatur

• 1 Bautmans I, Van Puyvelde K, Mets T. Sarcopenia and functional decline: pathophysiology, prevention and therapy.  Acta Clin Belg. 2009;  64 303-316
• 2 Bennani-Baiti N, Davis M P. Cytokines and cancer anorexia cachexia syndrome.  Am J Hosp Palliat Care. 2008;  25 407-411
• 3 Delano M J, Moldawer L L. The origins of cachexia in acute and chronic inflammatory diseases.  Nutr Clin Pract. 2006;  21 68-81
• 4 De Vriese C, Delporte C. Influence of ghrelin on food intake and energy homeostasis.  Curr Opin Clin Nutr Metab Care. 2007;  10 615-619
• 5 Eley H L, Russell S T, Tisdale M J. Role of the dsRNA-dependent protein kinase (PKR) in the attenuation of protein loss from muscle by insulin and insulin-like growth factor-1 (IGF-1).  Mol Cell Biochem. 2008;  313 63-69
• 6 Emmelot-Vonk M H, Verhaar H J, Nakhai Pour H R. et al . Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.  JAMA. 2008;  299 39-52
• 7 Evans W J, Morley J E, Argilés J. et al . Cachexia: a new definition.  Clin Nutr. 2008;  27 793-799
• 8 Fearon K C. Cancer cachexia: developing multimodal therapy for a multidimensional problem.  Eur J Cancer. 2008;  44 1124-1132
• 9 Foster A C, Chen C. Melanocortin-4 receptor antagonists as potential therapeutics in the treatment of cachexia.  Curr Top Med Chem. 2007;  7 1131-1136
• 10 Fox C B, Treadway A K, Blaszcyk A T, Sleeper R B. Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly.  Pharmacotherapy. 2009;  29 383-397
• 11 Frost R A, Lang C H. Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass.  J Appl Physiol. 2007;  103 378-387
• 12 Goldspink G. Loss of muscle strength during aging studied at the gene level.  Rejuvenation Res. 2007;  10 397-405
• 13 Goodpaster B H, Park S W, Harris T B. et al . The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study.  J Gerontol. 2006;  61A 1059-1064
• 14 Hubbard R E, O’Mahony M S, Calver B L, Woodhouse K W. Nutrition, inflammation, and leptin levels in aging and frailty.  J Am Geriatr Soc. 2008;  56 279-284
• 15 Huber K. Gezielte Ernährungstherapie gegen Tumorkachexie. Onkologie in der Praxis; 2003 Ärztewoche Wien
• 16 Jackson M J. Skeletal muscle aging: role of reactive oxygen species.  Crit Care Med. 2009;  37 S368-371
• 17 Jang Y C, Lustgarten M S, Liu Y. et al . Increased superoxide in vivo accelerates age-associated muscle atrophy through mitochondrial dysfunction and neuromuscular junction degeneration.  FASEB J. 2009; Epub ahead of print; 
• 18 Kaminji M M, Inui A. The role of ghrelin and ghrelin analogues in wasting disease.  Curr Opin Clin Nutr Metab Care. 2008;  11 443-451
• 19 Kishioka Y, Thomas M, Wakamatsu J. et al . Decorin enhances the proliferation and differentiation of myogenic cells through suppressing myostatin activity.  J Cell Physiol. 2008;  215 856-867
• 20 Kollias H D, McDermott J C. Transforming growth factor-beta and myostatin signaling in skeletal muscle.  J Appl Physiol. 2008;  104 579-587
• 21 Laviano A, Meguid M M, Inui A, Muscaritoli M, Rossi-Fanelli F. Therapy Insight: cancer anorexia-chachexia-syndrome – when all you can eat is yourself.  Review Nature Clinical Practice Oncology. 2005;  2 158-165
• 22 Liu C M, Yang Z, Liu C W. et al . Effect of RNA oligonucleotide Foxo-1 on muscle growth in normal and cancer cachexia mice.  Cancer Gene Ther. 2007;  14 945-952
• 23 Lundholm K, Daneryd P, Bosaeus I, Körner U, Lindholm E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism, and function.  Cancer. 2004;  100 1967-1977
• 24 Lundholm K, Körner U, Gunnebo L. et al . Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning.  Clin Cancer Res. 2007;  13 2699-2706
• 25 Lynch G S, Ryall J G. Role of beta-adrenoreceptor signaling in skeletal muscle: implications for muscle wasting and disease.  Physiol Rev. 2008;  88 729-767
• 26 Lynch G S, Schertzer J D, Ryall J G. Therapeutic approaches for muscle wasting disorders.  Pharmacol Ther. 2007;  113 461-487
• 27 Melstrom L G, Melstrom Jr K A, Ding X Z, Adrian T E. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia.  Histol Histopathol. 2007;  22 805-814
• 28 Norman K, Richard C, Lochs H, Pirlich M. Prognostic impact of disease-related malnutrition.  Clin Nutr. 2008;  27 5-15
• 29 Ockenga J, Pirlich M, Gastell S, Lochs H. Tumoranorexie – Tumorkachexie bei gastrointestinalen Tumoren: Standards und Visionen.  Z Gastroenterol. 2002;  40 929-936
• 30 Pahor M, Manini T, Cesari M. Sarcopenia: clinical evaluation, biological markers and other evaluation tools.  Nutr Health Aging. 2009;  13 724-728
• 31 Pascual Lopez A. Systematic reviews of megestrol acetate in the treatment of anorexia-cachexia syndrome.  J Pain Symptom Manage. 2004;  27 360-369
• 32 Pirlich M, Schütz T, Norman K. et al . The German hospital malnutrition study.  Clin Nutr. 2006;  25 563-572
• 33 Rensing L, Koch M, Rippe B, Rippe V. Mensch im Stress. Psyche, Körper, Moleküle. Heidelberg: Spektrum Akademischer Verlag, Elsevier; 2006
• 34 Russell S T, Eley H, Tisdale M J. Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II.  Cell Signal. 2007;  19 1797-1806
• 35 Ryall J G, Schertzer J D, Lynch G S. Cellular and molecular mechanisms underlying age-related muscle wasting and weakness.  Biogerontology. 2008;  9 213-228
• 36 Saini A, Faulkner S, Al-Shanti N, Stewart C. Powerful signal for weak muscles.  Ageing Res Rev. 2009;  8 251-67
• 37 Sakuma K, Yamaguchi A. Molecular mechanisms in aging and current strategies to counteract sarcopenia.  Curr Aging Sci. 2010;  3 90-101
• 38 Schmitt T L, Martignoni M E, Bachmann I. Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia.  J Mol Med. 2007;  85 647-654
• 39 Schülke M, Wagner K R, Stolz L E. et al . Myostatin mutation associated with gross muscle hypertrophy in a child.  N Engl J Med. 2004;  350 2682-2688
• 40 Sciorati C, Touvier T, Buono R. et al . Necdin is expressed in cachetic skeletal muscle to protect fibers from tumor-inducing wasting.  Cell Sci. 2009;  122 1119-1125
• 41 Senf S M, Dodd S L, McClung J M, Judge A R. Hsp70 overexpression inhibits NF-(kappa)B and Foxo3a transcriptional activities and prevents skeletal muscle atrophy.  FASEB J. 2008;  22 3836-3845
• 42 Short K R, Vittone J L, Bigelow M L. Changes in myosin heavy chain mRNA and protein expression in human skeletal muscle with age and endurance exercise training.  J Appl Physiol. 2005;  99 95-102
• 43 Strasser F. Appraisal of current and experimental approaches to the treatment of cachexia.  Curr Opin Support Palliat Care. 2007;  1 312-316
• 44 Szewczyk N J, Jacobson L A. Signal-transduction network and the regulation of muscle protein degradation.  IJBCB. 2005;  37 1997-2011
• 45 Thomas D R. Loss of skeletal muscle mass in aging: examining the relationship of starvation, sarcopenia and cachexia.  Clin Nutr. 2007;  26 389-399
• 46 Tisdale M J. Mechanisms of cancer cachexia.  Physiol Rev. 2009;  89 381-410
• 47 Todorov P T, Wyke S M, Tisdale M J. Identification and characterization of a membrane receptor for proteolysis-inducing factor on skeletal muscle.  Cancer Res. 2007;  67 11419-11427
• 48 Tsuchida K. Targeting myostatin for therapies against muscle-wasting disorders.  Curr Opin Drug Discov Devel. 2008;  11 487-494
• 49 von Haehling S, Lainscak M, Springer J, Anker S D. Cardiac cachexia: A systematic overview.  Pharmacol Therapeut. 2009;  121 227-252
• 50 Weyermann P, Dallmann R, Magyar J. et al . Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice.  PloS One. 2009;  4 e4774
• 51 Yavuzsen T, Walsh D, Davis M P. et al . Components of the anorexia-cachexia syndrome: gastrointestinal symptom correlates of cancer anorexia.  Support Care Cancer. 2009; Epub ahead of print; 
• 52 Zhao J, Brault J J, Schild A. et al . FOX03 coordinately activates protein degradation by the autophagic lysosmal and proteasomal pathways in atrophying muscle cells.  Cell Metab. 2007;  6 472-483
• 53 Zoico E, Roubenoff R. The role of cytokines in regulating protein metabolism and muscle function.  Nutr Rev. 2002;  60 39-51
• 54 Zürcher G. Medikamentöse Strategien zur Gewichtszunahme bei kachektischen Patienten.  Aktuelle Ernährungsmedizin. 2004;  27 398-407